Medicine guide

PAZOPANIB DR. REDDYS

As listed in the register: PAZOPANIB DR. REDDYS 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

400 mg · comprimido recubierto con película

  • Prescription only
  • Cancer treatments and immune-system medicines
Active substance
Pazopanib
Made by
Reddy Pharma Iberia S.A.

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Medicine groupCancer treatments and immune-system medicinesL01EX03

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

How it works

This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (pazopanib). It describes the substance, not this Bulgarian product — its uses and doses can differ.

In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors.

In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in a mouse model, and the growth of some human tumor xenografts in mice.

Half-life31 h
Mostly cleared after≈ 6 daysfive half-lives — our arithmetic
How the body breaks it down

In vitro studies demonstrated that pazopanib is metabolized by CYP3A4 with a minor contribution from CYP1A2 and CYP2C8.

With food

Effect of Food Systemic exposure to pazopanib is increased when administered with food.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-19

Safety of the active substance

This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (pazopanib). It describes the substance, not this Bulgarian product — its uses and doses can differ.

Serious warning

WARNING: HEPATOTOXICITY Severe and fatal hepatotoxicity has been observed in clinical trials.

Most common side effects

The most common adverse reactions in patients with STS (≥ 20%) are fatigue, diarrhea, nausea, decreased weight, hypertension, decreased appetite, vomiting, tumor pain, hair color changes, musculoskeletal pain, headache, dysgeusia, dyspnea, and skin hypopigmentation.

Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

European UnionNo exact match for this strength and form

CanadaNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byReddy Pharma Iberia S.A.
Active substancePazopanib
Used inCancer treatments and immune-system medicines
Strength400 mg
Formcomprimido recubierto con película
ClassificationL01EX03 · Cancer treatments and immune-system medicines
Routevía oral
MarketedYes, according to the register
SupplyThe regulator reports a supply problem for this product.
GenericYes — a generic medicine, according to the register
Name in the registerPAZOPANIB DR. REDDYS 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG
Nº Registro90229

Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician

Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.

Other strengths and forms

2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

  • comprimido recubierto con película2 products

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.